Dabigatran versus Warfarin in Patients with Atrial FibrillationStuart J. Connolly, Lars Wallentin, Susan Wang et al.|New England Journal of Medicine|2009Cited by 11.2k
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial FibrillationJohn W. Eikelboom, Salim Yusuf, Lars Wallentin et al.|Circulation|2011Cited by 1.1k
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trialLars Wallentin, Stuart J. Connolly, Salim Yusuf et al.|The Lancet|2010Cited by 1k
The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation PatientsPaul Reilly, Lars Wallentin, Thorsten Lehr et al.|Journal of the American College of Cardiology|2013Cited by 826
Newly Identified Events in the RE-LY TrialStuart J. Connolly, Lars Wallentin, Michael D. Ezekowitz et al.|New England Journal of Medicine|2010Cited by 681